Deciphera Reports Positive Phase 2a Results for PV Treatment Sapablursen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Source: Businesswire
- Clinical Trial Results: Deciphera presented positive Phase 2a results for sapablursen at the American Society of Hematology Annual Meeting, demonstrating its ability to reduce blood withdrawal frequency in polycythemia vera patients, potentially establishing it as a new treatment option.
- Drug Development Progress: Sapablursen has received Fast Track, orphan drug, and Breakthrough Therapy designations from the FDA, indicating its potential in treating polycythemia vera, with a Phase 3 study planned for 2026 to further validate its efficacy.
- Patient Burden Reduction: By decreasing the need for phlebotomy, sapablursen significantly alleviates the physical and psychological burdens on patients, improving their quality of life and addressing the urgent need for new therapies in this area.
- Collaboration and Licensing: Deciphera's exclusive global development and commercialization agreement with Ono Pharmaceutical reflects confidence in sapablursen's market potential, expected to accelerate its market introduction and clinical application.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
